Leads to better outcomes for liver resection
|
Categories |
Oncology / Cancer, Small molecule, Peptide / Protein |
|
Development Stage |
Proof of concept – initial animal trials in mice |
|
Patent Status |
International patent published |
|
Market |
The liver is the second most common site of metastasis after the lymph nodes. In the United States, there are between 64,000 and 80,000 cases of liver tumors metastatic from colorectal cancers alone each year. |
Highlights
-
Liver resection is currently the best therapy for cancer metastases in the liver.
-
The liver's ability to regenerate decreases with age.
-
The ability of older patients to withstand the treatment declines and mortality from the sugary, rather than the disease, increases.
Our Innovation
Pharmacological means to improve regeneration of liver in older patients.
The graph below shows increased mortality of aged mice treated with the drug after hepatectomy
Kaplan Meier plots depicting survival after hepatectomy in aged pregnant (pink), aged nonpregnant (blue), old (green) and drug-treated old (orange) mice.
Key Features
-
Increases chances of survival for patients suffering with metastases in the liver
-
Increases the number of elderly patients who are eligible for curative surgery
Development Milestones
Seeking funding for ongoing research and industrial cooperation for development
The Opportunity
-
In the Western world, metastasis to the liver is much more common than primary liver cancer.
-
Liver metastases are most commonly seen in patients aged 60 and above..
1586128900.png)